테라젠이텍스
Financials
Valuation Metrics
테라젠이텍스's Market Cap is ₩817B. At end of 2025 it was ₩1174B. Ranked #1375 of 2,436 in KR market (top 56%), #769 of 1,649 on KOSDAQ (top 47%), #151 of 234 in Pharmaceuticals, Biotechnology & Life Sciences (top 65%) by Market Cap.
Investment Metrics(as of 2026-08-04)
| Metric | Value | Rank |
|---|---|---|
| Size | ||
| Market Cap | 81.74B KRW | KR#1,375/2,436 Sec#151/234 |
| Revenue | 272.93B KRW | KR#852/2,436 Sec#41/234 |
| Net Income | 10.80B KRW | KR#881/2,436 Sec#56/234 |
| Total Assets | 253.33B KRW | KR#1,103/2,436 Sec#77/234 |
| Net Assets | 152.04B KRW | KR#1,098/2,436 Sec#78/234 |
| Employees | 214 | KR#1,040/2,436 Sec#86/234 |
| Value | ||
| P/E | 7.57x | KR#526/2,436 Sec#23/234 |
| P/B | 0.54x | KR#879/2,436 Sec#40/234 |
| P/S | 0.30x | KR#599/2,436 Sec#14/234 |
| EV/EBITDA | 16.37x | KR#907/2,436 Sec#52/234 |
| FCF Yield | 10.27% | KR#619/2,436 Sec#24/234 |
| Profitability | ||
| ROE | 7.10% | KR#777/2,436 Sec#56/234 |
| ROA | 4.26% | KR#747/2,436 Sec#64/234 |
| Op. Margin | 2.81% | KR#1,253/2,436 Sec#96/234 |
| Revenue Growth | 1.99% | KR#1,315/2,436 Sec#121/234 |
| Financial Health | ||
| Debt Ratio | 166.62% | KR#1,395/2,436 Sec#159/234 |
| Total Debt | 81.49B KRW | KR#792/2,436 Sec#53/234 |
| FCF | 8.40B KRW | KR#758/2,436 Sec#42/234 |
| Cash | 37.87B KRW | KR#882/2,436 Sec#56/234 |
| Current Ratio | 1.87x | KR#1,021/2,436 Sec#116/234 |
| Net Debt/EBITDA | 5.70x | KR#1,125/2,436 Sec#85/234 |
| Performance | ||
| 1Y Return | -25.42% | KR#1,454/2,436 Sec#125/234 |
| 1M Return | 6.02% | KR#414/2,436 Sec#33/234 |
| From 52W High | -36.60% | KR#622/2,436 Sec#42/234 |
| 1Y MDD | -43.05% | KR#627/2,436 Sec#49/234 |
| Trading | ||
| Volume | 77,130 shares | KR#1,089/2,436 Sec#105/234 |
| Foreign Own. | 2.33% | KR—/2,436 Sec—/234 |
| Per Share | ||
| EPS | 262 KRW | KR#1,132/2,436 Sec#78/234 |
| BPS | 3,590 KRW | KR#1,693/2,436 Sec#129/234 |
Company Info
Theragen Etex, established in 1990 and listed on KOSDAQ in 2004, adopted its current name after merging with Etex Pharmaceutical in 2010. The company primarily manufactures and sells specialized and general medicines and provides genome sequencing services, with Leadfarm, Theragen Healthcare, and Theragen Bio as subsidiaries. Theragen Etex focuses on new drug R&D, DNA sequencing, and RNA variant genome analysis to address future medical changes, and is pursuing global market expansion through its Chinese local subsidiary. It is headquartered in Ansan-si, Gyeonggi-do.